<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02112851</url>
  </required_header>
  <id_info>
    <org_study_id>PEP-1326</org_study_id>
    <nct_id>NCT02112851</nct_id>
  </id_info>
  <brief_title>Processed Orange and the Glycemic Response</brief_title>
  <acronym>POGR</acronym>
  <official_title>A Randomized, Placebo-controlled, Double-blind, Crossover Trial to Investigate the Effects of Acute Processed Whole Orange Consumption on Postprandial Glycemic Responses in Healthy Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PepsiCo Global R&amp;D</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PepsiCo Global R&amp;D</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, placebo controlled, double blind, postprandial crossover study in male subjects.&#xD;
      3 intervention arms, consisting of a control (Product A), a low dose processed whole orange&#xD;
      (Product B) and a high dose processed whole orange (Product C), to determine the effect of&#xD;
      the interventions on the primary endpoint of postprandial glycemia. Secondarily, plasma&#xD;
      insulin concentrations will be quantified.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study design is a randomized, placebo controlled, double-blind, crossover. This trial&#xD;
      will include 33 subjects randomized to receive products A, B or C [240 mL (255 g)]. Subjects&#xD;
      will be randomly assigned to one of 6 sequences of 3 interventions. After the initial&#xD;
      screening visit, subjects will visit the Clinical and Translational Research Center (CTRC)&#xD;
      the Tufts Translational and Clinical Science Institute (CTSI) on three separate occasions.&#xD;
      Following each intervention day there will be a two week wash out period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 7, 2014</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma glucose concentration (Cmax)</measure>
    <time_frame>0-8 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma insulin concentration (Cmax)</measure>
    <time_frame>0-8 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC) of glucose and insulin and the time to reach Cmax gluc (Tmax gluc) and Cmax ins (Tmax ins)</measure>
    <time_frame>0-8 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Maximum Observed Plasma Glucose Concentration (Cmax)</condition>
  <arm_group>
    <arm_group_label>Orange flavored beverage</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>240ml orange beverage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Orange flavored beverage - Test1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>240ml processed whole orange low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Orange flavored beverage - Test2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>240ml processed whole orange high dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Orange flavored beverage</intervention_name>
    <description>Intervention involves consumption of one beverage of 240ml following baseline measurements</description>
    <arm_group_label>Orange flavored beverage</arm_group_label>
    <arm_group_label>Orange flavored beverage - Test1</arm_group_label>
    <arm_group_label>Orange flavored beverage - Test2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males (due to potential hormonal fluctuations in female subjects) aged 30-65 y&#xD;
&#xD;
          -  BMI: 25-29.9 kg/m2&#xD;
&#xD;
          -  Not diabetic [diagnosed or fasting glucose &gt;7 mmol/L (126 mg/dL)] or suffer from other&#xD;
             endocrine disorders&#xD;
&#xD;
          -  Not having suffered a myocardial infarction/stroke in the past 12 mo&#xD;
&#xD;
          -  Not suffering from renal or bowel disease or have a history of choleostatic liver or&#xD;
             pancreatitis&#xD;
&#xD;
          -  Not on drug treatment for hyperlipidaemia, hypertension, inflammation or&#xD;
             hypercoagulation&#xD;
&#xD;
          -  No history of alcohol misuse&#xD;
&#xD;
          -  Not planning or on a weight reducing regime&#xD;
&#xD;
          -  Not taking any fish oil, fatty acid or vitamin and mineral supplements&#xD;
&#xD;
          -  Non smokers&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Females&#xD;
&#xD;
          -  Use of medications known to affect lipid metabolism, i.e., hypolipidemic or&#xD;
             cholesterol-lowering agents (e.g., Pravastatin, Simuvustatin)&#xD;
&#xD;
          -  Use of (&gt;2x/wk) medication for inflammation or hypercoagulation&#xD;
&#xD;
               -  Anticoagulants (Warfarin)&#xD;
&#xD;
               -  Inflammation - NSAID's (Tiaprofenic acid, Sulindac, Ibuprofen), Corticosteroids&#xD;
                  (Betamethasone)&#xD;
&#xD;
          -  Regular use (&gt;2x/wk) of any acid-lowering medications, laxatives or anti-diarrheal&#xD;
             medications (prescription or over-the-counter [OTC])&#xD;
&#xD;
          -  Use of medications known or suspected to influence blood pressure, including&#xD;
             beta-adrenergic blocking agents (oral or ocular) (e.g., Sotalol, Bisoprolol),&#xD;
             beta-adrenergic drugs, calcium channel blocking agents (Amlodipine, Nicardipine),&#xD;
             angiotensin converting enzyme (ACE) inhibitors (Captopril, Cilazapril), angiotensin&#xD;
             receptor blocking agents (Valsartan), nitrates, diuretics (Chlortalidone), venlafaxine&#xD;
             and sibutramine, decongestants or chloroquine&#xD;
&#xD;
          -  Systolic blood pressure &gt;150 mmHg and/or diastolic blood pressure &gt;95 mmHg&#xD;
&#xD;
          -  CVD including coronary artery disease, left ventricular hypertrophy, congestive heart&#xD;
             failure, cerebrovascular disease, stroke, peripheral vascular disease or dysautonomia&#xD;
&#xD;
          -  Gastrointestinal diseases conditions or medications influencing gastrointestinal&#xD;
             absorption including active peptic ulcer disease, treatment with acid-lowering drugs&#xD;
             or inflammatory bowel disease&#xD;
&#xD;
          -  Renal or chronic kidney disease due to any condition, renovascular disease, history of&#xD;
             nephrolithiasis or serum creatinine &gt;1.5 mg/dL&#xD;
&#xD;
          -  Endocrine disorders including diabetes [fasting blood glucose &gt;7 mmol/L (126 mg/dL) or&#xD;
             current pharmacologic treatment for diabetes], untreated thyroid disease, adrenal&#xD;
             disease, pheochromocytoma, parathyroid disease or hyperuricemia&#xD;
&#xD;
          -  Rheumatologic diseases including gout or inflammatory arthritis&#xD;
&#xD;
          -  Active treatment for cancer of any type (except basal cell carcinoma)&lt;1 y&#xD;
&#xD;
          -  Regular use of oral steroids except topical OTC steroids&#xD;
&#xD;
          -  Regular use of any dietary supplements containing vitamins, minerals, herbal or other&#xD;
             plant-based preparations, fish oil supplements (including cod liver oil) or&#xD;
             homeopathic remedies. However, subjects who are willing to refrain from the use of&#xD;
             these supplements for 1 mo prior to their initial visit (Visit 3) may be considered&#xD;
             eligible.&#xD;
&#xD;
          -  Usual daily ethanol intake of&gt;2 drinks (24 oz beer, 8 oz wine, 2 oz hard liquor)&#xD;
&#xD;
          -  Cigarette smoking and/or nicotine replacement use. However, subjects who have stopped&#xD;
             using these products for 1 y prior to their initial visit (Visit 1) may be considered&#xD;
             eligible.&#xD;
&#xD;
          -  Illicit drug use&#xD;
&#xD;
          -  Infrequent (&lt;3/wk) or excessive (&gt;3/d) number of regular bowel movements&#xD;
&#xD;
          -  Specific laboratory blood or urine analysis parameters of:&#xD;
&#xD;
               -  Creatinine &gt; 1.5 mg/dL&#xD;
&#xD;
               -  Electrolytes, calcium, phosphorous - out of normal ranges&#xD;
&#xD;
               -  ALT and AST &gt;1.5 nmol&#xD;
&#xD;
               -  Total bilirubin - above normal range&#xD;
&#xD;
               -  Triglycerides ≥300 mg/dL&#xD;
&#xD;
               -  Fasting glucose ≥126 mg/dL&#xD;
&#xD;
               -  CBC: HCT outside of normal NEL reference ranges at the discretion of the study&#xD;
                  physician&#xD;
&#xD;
               -  WBC, PLT - outside of normal NEL reference ranges Strict vegetarians&#xD;
&#xD;
          -  Those on or planning a weight reducing regime&#xD;
&#xD;
          -  Unable to consume study meals or products&#xD;
&#xD;
          -  Subjects with larger than 5 kg weight loss in the last 3 months.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tufts University</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 10, 2014</study_first_submitted>
  <study_first_submitted_qc>April 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2014</study_first_posted>
  <last_update_submitted>March 8, 2021</last_update_submitted>
  <last_update_submitted_qc>March 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

